See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a biologic medication used to treat various inflammatory diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While generally well-tolerated, Cosentyx can cause side effects that may require dose adjustments. The following side effects may necessitate dose adjustments:

1. Infections: Cosentyx can increase the risk of infections, including serious infections such as tuberculosis (TB) and fungal infections. Patients with a history of TB or other infections may require dose adjustments or alternative treatments.
2. Hypersensitivity reactions: Rare cases of anaphylaxis and other hypersensitivity reactions have been reported. Patients experiencing severe allergic reactions may require dose adjustments or discontinuation of treatment.
3. Hepatitis B reactivation: Cosentyx can reactivate hepatitis B virus (HBV) in patients with a history of HBV infection. Patients with a history of HBV infection may require dose adjustments or alternative treatments.
4. Increased liver enzymes: Elevated liver enzymes (ALT and AST) have been reported in some patients. Patients with pre-existing liver disease or elevated liver enzymes may require dose adjustments or alternative treatments.
5. Neurological side effects: Rare cases of seizures, paresthesia, and peripheral neuropathy have been reported. Patients experiencing severe neurological side effects may require dose adjustments or discontinuation of treatment.

It is essential to monitor patients closely for these side effects and adjust the dose of Cosentyx accordingly. Healthcare providers should consider the patient's medical history, current medications, and laboratory results when making dose adjustments.

Sources:

1. Cosentyx Prescribing Information [1]
2. DrugPatentWatch.com - Cosentyx (secukinumab) [2]
3. National Psoriasis Foundation - Cosentyx [3]
4. European Medicines Agency - Cosentyx [4]

References:

[1] Novartis Pharmaceuticals Corporation. (2022). Cosentyx Prescribing Information.

[2] DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab). Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>

[3] National Psoriasis Foundation. (n.d.). Cosentyx. Retrieved from <https://www.psoriasis.org/treatments/cosentyx/>

[4] European Medicines Agency. (2022). Cosentyx. Retrieved from <https://www.ema.europa.eu/en/medicines/human/000969>